Catherine Ibarra-Drendall

Summary

Affiliation: Duke University Medical Center
Country: USA

Publications

  1. ncbi Pilot and feasibility study: prospective proteomic profiling of mammary epithelial cells from high-risk women provides evidence of activation of pro-survival pathways
    Catherine Ibarra-Drendall
    Division of Medical Oncology, Duke University Medical Center, Box 2628, Durham, NC 27710, USA
    Breast Cancer Res Treat 132:487-98. 2012
  2. ncbi Purification and characterization of recombinant CH3 domain fragment of the CREB-binding protein
    Catherine Ibarra Drendall
    Department of Medicine, Duke University Medical Center, Box 2628, Durham, NC 27710, USA
    Protein Expr Purif 70:196-205. 2010
  3. ncbi Protein microarray analysis of mammary epithelial cells from obese and nonobese women at high risk for breast cancer: feasibility data
    Patrick G Pilie
    Duke University Medical Center, Box 2628, Durham, NC 27710, USA
    Cancer Epidemiol Biomarkers Prev 20:476-82. 2011
  4. ncbi CpG island tumor suppressor promoter methylation in non-BRCA-associated early mammary carcinogenesis
    Shauna N Vasilatos
    Department of Medicine, Duke University Medical Center, Box 2628, Durham, NC 27710, USA
    Cancer Epidemiol Biomarkers Prev 18:901-14. 2009
  5. ncbi ESR1 promoter hypermethylation does not predict atypia in RPFNA nor persistent atypia after 12 months tamoxifen chemoprevention
    Joseph C Baker
    Duke University Medical Center, Durham, NC 27710, USA
    Cancer Epidemiol Biomarkers Prev 17:1884-90. 2008
  6. ncbi Reproducibility of random periareolar fine needle aspiration in a multi-institutional Cancer and Leukemia Group B (CALGB) cross-sectional study
    Catherine Ibarra-Drendall
    Duke University Medical Center, Durham, NC 27710, USA
    Cancer Epidemiol Biomarkers Prev 18:1379-85. 2009
  7. ncbi Breast self-examination: defining a cohort still in need
    Lee G Wilke
    Duke University, Department of Surgery, Durham, NC, USA
    Am J Surg 198:575-9. 2009
  8. ncbi Hypermethylation of the breast cancer-associated gene 1 promoter does not predict cytologic atypia or correlate with surrogate end points of breast cancer risk
    Gregory R Bean
    Duke University Medical Center, Box 2628, Durham, NC 27710, USA
    Cancer Epidemiol Biomarkers Prev 16:50-6. 2007

Collaborators

Detail Information

Publications8

  1. ncbi Pilot and feasibility study: prospective proteomic profiling of mammary epithelial cells from high-risk women provides evidence of activation of pro-survival pathways
    Catherine Ibarra-Drendall
    Division of Medical Oncology, Duke University Medical Center, Box 2628, Durham, NC 27710, USA
    Breast Cancer Res Treat 132:487-98. 2012
    ....
  2. ncbi Purification and characterization of recombinant CH3 domain fragment of the CREB-binding protein
    Catherine Ibarra Drendall
    Department of Medicine, Duke University Medical Center, Box 2628, Durham, NC 27710, USA
    Protein Expr Purif 70:196-205. 2010
    ..Our results suggest that Akt signaling may have important implications on the in vivo molecular interaction of CBP with various transcription factors and modulation of cellular responses...
  3. ncbi Protein microarray analysis of mammary epithelial cells from obese and nonobese women at high risk for breast cancer: feasibility data
    Patrick G Pilie
    Duke University Medical Center, Box 2628, Durham, NC 27710, USA
    Cancer Epidemiol Biomarkers Prev 20:476-82. 2011
    ....
  4. ncbi CpG island tumor suppressor promoter methylation in non-BRCA-associated early mammary carcinogenesis
    Shauna N Vasilatos
    Department of Medicine, Duke University Medical Center, Box 2628, Durham, NC 27710, USA
    Cancer Epidemiol Biomarkers Prev 18:901-14. 2009
    ..Only 5% of all breast cancers are the result of BRCA1/2 mutations. Methylation silencing of tumor suppressor genes is well described in sporadic breast cancer; however, its role in familial breast cancer is not known...
  5. ncbi ESR1 promoter hypermethylation does not predict atypia in RPFNA nor persistent atypia after 12 months tamoxifen chemoprevention
    Joseph C Baker
    Duke University Medical Center, Durham, NC 27710, USA
    Cancer Epidemiol Biomarkers Prev 17:1884-90. 2008
    ..Currently, we lack biomarkers to predict whether high-risk women with mammary atypia will respond to tamoxifen chemoprevention...
  6. ncbi Reproducibility of random periareolar fine needle aspiration in a multi-institutional Cancer and Leukemia Group B (CALGB) cross-sectional study
    Catherine Ibarra-Drendall
    Duke University Medical Center, Durham, NC 27710, USA
    Cancer Epidemiol Biomarkers Prev 18:1379-85. 2009
    ..To address these key limitations, the Cancer and Leukemia Group B (CALGB) Prevention Group tested the reproducibility of RPFNA in a multi-institutional cross-sectional study...
  7. ncbi Breast self-examination: defining a cohort still in need
    Lee G Wilke
    Duke University, Department of Surgery, Durham, NC, USA
    Am J Surg 198:575-9. 2009
    ..The value of breast self-examination (BSE) to detect early breast cancer is controversial...
  8. ncbi Hypermethylation of the breast cancer-associated gene 1 promoter does not predict cytologic atypia or correlate with surrogate end points of breast cancer risk
    Gregory R Bean
    Duke University Medical Center, Box 2628, Durham, NC 27710, USA
    Cancer Epidemiol Biomarkers Prev 16:50-6. 2007
    ....